Zolmitriptan API Manufacturers

Looking for Zolmitriptan API 139264-17-8?

Description:

Here you will find a list of producers, manufacturers and distributors of Zolmitriptan. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Zolmitriptan 

Synonyms:

Zolmitriptan , Zolmitriptanum , Zomig  

Cas Number:

139264-17-8 

DrugBank number:

DB00315 

Unique Ingredient Identifier:

2FS66TH3YW

Zolmitriptan is a type of Selective 5HT1-agonists

Selective 5HT1-agonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various neurological and psychiatric disorders. These compounds specifically target and activate the 5HT1 receptor subtype, which belongs to the serotonin (5-hydroxytryptamine) receptor family. The 5HT1 receptor is primarily found in the central nervous system and is involved in regulating neurotransmitter release, mood, pain perception, and vasoconstriction.

Selective 5HT1-agonists have demonstrated therapeutic potential in the management of several conditions, including migraines, cluster headaches, and depression. By binding to and activating the 5HT1 receptor, these APIs can modulate serotonin levels in the brain, leading to a cascade of neurochemical events that alleviate symptoms associated with these disorders.

One of the key advantages of selective 5HT1-agonists is their targeted action, focusing specifically on the 5HT1 receptor without significant interactions with other receptor subtypes. This selectivity reduces the risk of adverse effects and improves the overall safety profile of these APIs.

Moreover, selective 5HT1-agonists often exhibit high affinity for the 5HT1 receptor, enhancing their efficacy and therapeutic potential. Through their agonistic activity, these compounds can regulate the release of neurotransmitters and modulate pain pathways, offering relief to patients suffering from debilitating migraines or cluster headaches.

In summary, selective 5HT1-agonists are a valuable subcategory of pharmaceutical APIs that provide targeted and effective treatment options for various neurological and psychiatric disorders. Their ability to selectively activate the 5HT1 receptor offers therapeutic benefits with reduced side effects, making them an essential component in the management of conditions such as migraines, cluster headaches, and depression.

Zolmitriptan (Selective 5HT1-agonists), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Jubilant Pharmova from India, product country of origin India
• LGM Pharma from United States, product country of origin World
• Unichem Labs. from India, product country of origin India
• Natco Pharma from India, product country of origin India
• Teva API from Israel, product country of origin Unknown
• PLIVA from Czech Republic, product country of origin Croatia
• Syn-tech Chem from Taiwan, product country of origin Taiwan
• Emcure Pharma from India, product country of origin India
• Sun Pharma from India, product country of origin India
• Hetero Drugs from India, product country of origin India
• Mylan from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.